Bayer’s new heart failure drug Verquvo (vericiguat) has been granted reimbursement listing in Korea, showing effect in high-risk patients. Based on the positive clinical results, experts have been claiming that Verquvo should be considered as a second-line treatment option.

On the 16th, Bayer Korea held a press conference celebrating the reimbursement listing of Verquvo in Korea at the Seoul Conrad Hotel in Yeouido.

Verquvo is an oral soluble Guanylate Cyclase (sGC) stimulator that plays an important role in the signaling pathway. The drug was approved in November 2021 and listed with reimbursement in September this year.

Patients with symptomatic chronic heart fa